Equities Analysts Set Expectations for ARTL FY2024 Earnings

Artelo Biosciences, Inc. (NASDAQ:ARTL) – Equities researchers at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Artelo Biosciences in a report issued on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings of ($2.62) per share for the year, down from their prior forecast of ($2.41). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Artelo Biosciences’ Q4 2024 earnings at ($0.74) EPS and FY2025 earnings at ($1.61) EPS.

Artelo Biosciences (NASDAQ:ARTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06.

Separately, EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st.

Artelo Biosciences Price Performance

Shares of NASDAQ ARTL opened at $1.04 on Monday. The company has a market capitalization of $3.36 million, a P/E ratio of -0.36 and a beta of 1.35. The company has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $1.27. Artelo Biosciences has a 1 year low of $1.00 and a 1 year high of $1.75.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.